Effect of Dexmedetomidine on Inflammatory Response in Aortic Dissection

Abstract

Objective: To study the effect of dexmedetomidine (Dex) on perioperative inflammatory response in aortic dissection (AD) patients. Methods: From June 2020 to June 2022, 50 patients with Stanford type B AD underwent endovascular stent-graft exclusion (EVAR) at our hospital. They randomly were assigned to two groups (N = 25): the control group (C group) and the Dex group. Patients in the Dex group received 0.5ug/kg Dex intravenously 10 minutes before induction of anesthesia and 0.5µg/kg/h Dex during the intervention until 15 minutes before the end of surgery. In contrast, the C group received the same volume of normal saline at the same time points. The two groups were induced and maintained with the same anesthetic agents. Venous blood samples were taken 3 days before operation (T1), 1 day before operation (T2), 1 day after operation (T3) and 3 days after operation (T4) to detect levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood cell count (WBC). Results: At T3 and T4, CRP and ESR in the Dex group were significantly improved compared with those in the C group. Conclusion: Dexmedetomidine can reduce the inflammatory reaction of aortic dissection.

Independent and Interactive Roles of Immunity and Metabolism in Aortic Dissection

“…This finding suggests that the inflammatory response may play an important role in the early onset of AD and can activate multiple pathological processes to further promote the onset of AD. Furthermore, immune cells such as macrophages, lymphocytes and neutrophils are often detected in the media and adventitia of AD tissues [16,17]. Moreover, abnormal carbohydrate, lipid and amino acid metabolism has gained increasing attention recently.…”